MaxCyte director granted RSUs and stock options
MAXCYTE, INC. director Stanley C. Erck received equity-based compensation in the form of restricted stock units and stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MAXCYTE, INC. director Stanley C. Erck received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one common share, and an option for 49,579 shares at an exercise price of $1.13 per share, expiring on June 16, 2036. The RSUs vest on June 17, 2027, subject to his continued service, and his direct common stock holdings after the grant total 428,749 shares.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
2 txns
Insider
Erck Stanley C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 49,579 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,421 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 49,579 contracts (Direct);
Common Stock — 428,749 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Key Figures
RSU grant: 30,421 RSUs
Stock option grant: 49,579 shares
Option exercise price: $1.13 per share
+2 more
5 metrics
RSU grant
30,421 RSUs
Annual non-employee director grant; each equals one common share
Stock option grant
49,579 shares
Option on common stock granted to director
Option exercise price
$1.13 per share
Strike price for 49,579-share stock option
Option expiration
June 16, 2036
Expiration date of stock option grant
Shares held after grant
428,749 shares
Director’s direct common stock holdings after RSU grant
Key Terms
restricted stock units ("RSUs"), contingent right, Equity Grant Policy, non-employee directors, +1 more
5 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
Equity Grant Policy financial
"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."
non-employee directors financial
"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 1.1300 per share."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MaxCyte (MXCT) director Stanley C. Erck receive in this Form 4 filing?
Stanley C. Erck received equity awards consisting of 30,421 restricted stock units and a stock option for 49,579 shares. These compensation grants increase his potential ownership stake through both time-vested RSUs and options tied to MaxCyte’s common stock.
How many MaxCyte (MXCT) restricted stock units were granted to director Erck?
He was granted 30,421 restricted stock units, each equal to one share of MaxCyte common stock. These RSUs form part of his annual non-employee director compensation and will only deliver shares if the vesting conditions are satisfied.
When do Stanley C. Erck’s MaxCyte (MXCT) RSUs vest?
The RSUs vest on June 17, 2027, if he continues serving as a director through that date. Vesting means the contingent right to receive one share per RSU converts into actual common stock ownership at that time.
What are the key terms of the MaxCyte (MXCT) stock option granted to Erck?
He received a stock option covering 49,579 MaxCyte common shares at an exercise price of $1.13 per share. The option expires on June 16, 2036, giving him a long-dated right to buy shares at that fixed price.
What policy governs these MaxCyte (MXCT) equity awards to the director?
The filing states the annual equity grant was made under MaxCyte’s Equity Grant Policy for non-employee directors. This policy standardizes how outside directors are compensated with RSUs and stock options each year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
